Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Ascending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
51991-0823-28 51991-0823 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 5, 2021 In Use
51991-0823-33 51991-0823 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 5, 2023 In Use
51991-0824-28 51991-0824 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
51991-0824-33 51991-0824 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 5, 2023 In Use
54288-0164-01 54288-0164 Carboplatin CARBOPLATIN 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 31, 2023 In Use
54288-0165-01 54288-0165 Carboplatin CARBOPLATIN 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 31, 2023 In Use
54288-0166-01 54288-0166 Carboplatin CARBOPLATIN 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 31, 2023 In Use
54288-0167-01 54288-0167 Carboplatin CARBOPLATIN 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 31, 2023 In Use
55150-0391-01 55150-0391 BENDAMUSTINE HYDROCHLORIDE BENDAMUSTINE HYDROCHLORIDE 25.0 mg/5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 5, 2023 In Use
57894-0050-60 57894-0050 NIRAPARIB TOSYLATE MONOHYDRATE and ABIRATERONE ACETATE AKEEGA 500.0 mg/1, 50.0 mg/1 Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP 17, PARP Oral Aug. 11, 2023 In Use
57894-0100-60 57894-0100 NIRAPARIB TOSYLATE MONOHYDRATE and ABIRATERONE ACETATE AKEEGA 500.0 mg/1, 100.0 mg/1 Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP17, PARP Oral Aug. 11, 2023 In Use
60505-6095-00 60505-6095 Bendamustine Hydrochloride Bendamustine Hydrochloride 25.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 19, 2023 In Use
60505-6096-00 60505-6096 Bendamustine hydrochloride Bendamustine Hydrochloride 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 19, 2023 In Use
60505-6272-01 60505-6272 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous July 1, 2023 In Use
60505-6277-00 60505-6277 CISplatin CISplatin 50.0 mg/50mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 6, 2023 In Use
62135-0772-35 62135-0772 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Aug. 29, 2023 In Use
63304-0116-13 63304-0116 Pazopanib Pazopanib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms Oral Oct. 20, 2023 In Use
63304-0116-30 63304-0116 Pazopanib Pazopanib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms Oral Oct. 20, 2023 In Use
63539-0051-30 63539-0051 Talazoparib Talzenna 0.5 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 21, 2023 In Use
63759-3048-01 63759-3048 Pemetrexed disodium Pemetrexed 100.0 mg/10mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 3, 2023 In Use
63759-3049-01 63759-3049 Pemetrexed disodium Pemetrexed 500.0 mg/50mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 3, 2023 In Use
63759-3050-01 63759-3050 Pemetrexed disodium Pemetrexed 1000.0 mg/100mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 3, 2023 In Use
63850-0058-01 63850-0058 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 5, 2021 In Use
63850-0058-04 63850-0058 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral May 26, 2023 In Use
63850-0059-01 63850-0059 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 5, 2021 In Use

Found 10,000 results in 7 milliseconds — Export these results